Over the last 2 decades, the outcomes for patients with multiple myeloma have dramatically improved. Immunomodulatory therapies are key constituent......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
In the nontransplant setting, continuous therapy may involve a doublet or a triplet regimen as tolerated until disease progression. After the more ......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
Immunomodulatory drugs act through multiple mechanisms, some of which have yet to be fully characterized. In addition to pairings with proteasome i......READ MORE
In both transplant and nontransplant populations, a careful balance between disease control, side effects, and quality of life must be maintained. ......READ MORE
High-risk smoldering multiple myeloma represents a subset of disease that is more likely to progress to active multiple myeloma. Efforts to refine ......READ MORE
Cytogenetic changes in multiple myeloma are among the most important prognostic factors, and treatments may have implications on the accumulation o......READ MORE
